October 18, 2022
RFA-HG-22-008 - Multi-Omics for Health and Disease - Disease Study Sites (U01 Clinical Trial Optional)
RFA-HG-22-009 - Multi-Omics for Health and Disease - 'Omics Production Centers (U01 Clinical Trial Not Allowed)
RFA-HG-22-010 - Multi-Omics for Health and Disease - Data Analysis and Coordination Center (U01 Clinical Trial Not Allowed)
NOT-HG-23-006 - Notice of Change in the Number of Disease Study Sites (DSSs) in RFA-HG-22-008 “Multi-Omics for Health and Disease - Disease Study Sites (U01 Clinical Trial Optional)”
NOT-HG-23-007 - Notice of Change in the Number of Disease Study Sites (DSSs) in RFA-HG-22-009 “Multi-Omics for Health and Disease - 'Omics Production Centers (U01 Clinical Trial Not Allowed)”
NOT-HG-23-008 - Notice of Change in the Number of Disease Study Sites (DSSs) in RFA-HG-22-010 “Multi-Omics for Health and Disease - Data Analysis and Coordination Center (U01 Clinical Trial Not Allowed)”
National Human Genome Research Institute (NHGRI)
In September 2022, the NHGRI, in collaboration with NCI and NIEHS, issued three related Funding Opportunity Announcements (FOAs): RFA-HG-22-008 “Multi-Omics for Health and Disease - Disease Study Sites (U01 Clinical Trial Optional)”; RFA-HG-22-009 “Multi-Omics for Health and Disease - 'Omics Production Centers (U01 Clinical Trial Not Allowed)”; and RFA-HG-22-010 “Multi-Omics for Health and Disease - Data Analysis and Coordination Center (U01 Clinical Trial Not Allowed).” Notices for a change in the number of Disease Study Sites (DSSs) in each RFA were released in October 2022: NOT-HG-23-006; NOT-HG-23-007; NOT-HG-23-008.
As a result of discussions with potential applicants, we are providing a list of Frequently Asked Questions (FAQs) and answers that are relevant to all three RFAs.
The FAQs for these FOAs can be found at: https://www.genome.gov/research-funding/Funded-Programs-Projects/Multi-Omics-for-Health-and-Disease. This information may be updated periodically without additional notice. NHGRI staff will also respond to questions submitted by potential applicants who contact the program, grants management, or review staff listed in the FOAs in the Agency Contacts section.
Please direct all inquiries related to RFA-HG-22-008; RFA-HG-22-009; and RFA-HG-22-010 to the Multi-Omics for Health and Disease Program to:
Email: [email protected].
and Human Services (HHS)
